Company intelligence / Profile preview

Royalty Opportunities

New York, New York, United States

Ownership: Private
Employees: ~35
Development stage: Other

Overview

Royalty Pharma is the largest acquirer of biopharmaceutical royalties, with a portfolio that includes royalties on blockbuster drugs like Trikafta, Imbruvica, Xtandi, Tysabri, and more. Its investment results are directly linked to the success of these products.

Therapeutic areas: ImmunologyInfectious DiseasesRare DiseasesCardiovascularOncologyNeurology
Modalities: Small moleculeMonoclonal antibodyRNA therapyGene therapyBiologicAntibody-drug conjugate
Industry: Investors

Beyond the preview

Go deeper on Royalty Opportunities.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Royalty Opportunities.

Explore the full profile